Shimon Citron - Jun 30, 2022 Form 3 Insider Report for Artemis Therapeutics, Inc. (ATMS)

Role
Chief Executive Officer, Director
Signature
/s/ Shimon Citron
Stock symbol
ATMS
Transactions as of
Jun 30, 2022
Transactions value $
$0
Form type
3
Date filed
8/12/2022, 04:05 PM

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ATMS Common Stock 15.7M Jun 30, 2022 Direct
holding ATMS Common Stock 10.4M Jun 30, 2022 By Spouse F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ATMS Series D Preferred Stock Jun 30, 2022 Common Stock 32.8M Direct F2, F3, F4
holding ATMS Series D Preferred Stock Jun 30, 2022 Common Stock 21.8M By Spouse F1, F2, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are beneficially owned by Mr. Citron's spouse, Sigal Citron. Mr. Citron disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.
F2 Upon the Issuer's increase of its authorized shares of Common Stock, expected in September 2022, all shares of Series D Preferred Stock will automatically convert into the Issuer's Common Stock.
F3 The Series D Preferred Stock has no expiration date.
F4 Each share of Series D Preferred Stock will convert into 600 shares of the Issuer's Common Stock.